Harris & Harris Group (TINY) 3.24 $TINY
ORIG3N(TM) Closes $3.1 Million in Funding Lead by Hatteras Venture Partners
PR Newswire - Thu Feb 05, 10:30AM CST
ORIG3N, Inc., a pioneer in regenerative medicine and provider of pluripotent stem cell storage, has raised $3.1 million in funding from an investor syndicate that includes Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital. The funding will be used to expand Life Capsule(TM) which provides everyone the opportunity to contribute to the advancement of medical research of rare genetic inherited diseases and neurodegenerative diseases such as Parkinson's, Alzheimer's, MS and ALS.
TINY: 3.24 (+0.06)
BDCA Venture Switches Investment Strategy, Should Investors Follow?
Chris Katje - at Seeking Alpha - Mon Feb 02, 11:05PM CST
TINY: 3.24 (+0.06), MM: 1.67 (+0.07), TRUE: 19.55 (+0.12), BDCV: 4.95 (+0.07)
Harris & Harris Group Portfolio Company D-Wave Systems Raises an Additional $29 Million (CAD), Closing 2014 Financing at $62 Million (CAD)
GlobeNewswire - Fri Jan 30, 9:40AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by portfolio company, D-Wave Systems, Inc., that it has closed $29 million (CAD) in funding from a large institutional investor, among others. This funding will be used to accelerate development of D-Wave's quantum hardware and software and expand the software application ecosystem. This investment brings total funding in D-Wave to $174 million (CAD), with approximately $62 million (CAD) raised in 2014. Harris & Harris Group's total investment in D-Wave is approximately $5.8 million (USD). D-Wave's announcement also includes highlights of 2014, a year of strong growth and advancement for D-Wave.
TINY: 3.24 (+0.06)
BDCL Next Quarterly Dividend Will Result In A 20.2% Yield
Lance Brofman - at Seeking Alpha - Fri Dec 26, 2:49PM CST
ACAS: 14.68 (+0.14), MAIN: 30.82 (+0.23), TCAP: 22.52 (+0.37), CEFL: 22.43 (+0.06), MTGE: 18.33 (+0.01), CSWC: 46.54 (+1.20), AGNC: 21.95 (+0.21), BDCS: 22.99 (+0.10), MORL: 19.93 (+0.09), TAXI: 9.92 (+0.13), TINY: 3.24 (+0.06), TCPC: 16.39 (+0.17), SPY: 209.78 (+0.86), BDCL: 21.37 (+0.33), ARCC: 16.85 (+0.01), MCGC: 3.84 (-0.01), TSLX: 17.78 (+0.07), ACSF: 12.81 (+0.04), GAIN: 7.69 (+0.05), PSEC: 8.67 (+0.07)
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 3.24 (+0.06), MRK: 58.81 (-0.07)
Harris & Harris Group's (TINY) CEO Douglas Jamison on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:40AM CST
TINY: 3.24 (+0.06)
Harris & Harris reports Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:49AM CST
TINY: 3.24 (+0.06)
Harris & Harris Group Reports Financial Statements as of September 30, 2014
GlobeNewswire - Mon Nov 10, 4:09PM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, reported today that, as of September 30, 2014, its net asset value and net asset value per share were $120,158,974 and $3.85, respectively. The firm has made significant new investments in new emerging areas of science. It has seen growth within its portfolio as its companies continue to execute in their respective industries.
TINY: 3.24 (+0.06)
Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Mon Nov 03, 2:53PM CST
The management of Harris & Harris Group, Inc., (Nasdaq:TINY), will hold a conference call to discuss the Company's financial results for its third quarter 2014, to update shareholders and analysts on our business and to answer questions, on Wednesday, November 12, 2014, at 10:00 a.m. Eastern Time.
TINY: 3.24 (+0.06)
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies
GlobeNewswire - Wed Oct 22, 8:52AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, continues its track record of early stage investments in emerging new technologies through a capital commitment and formation of TARA Biosystems (www.tarabiosystems.com). Based on research out of Columbia University, the Radisic Laboratory and MIT, TARA Biosystems aims to capitalize on the need for more effective processes for evaluating the safety and efficacy of new therapies and new drug compounds. TARA Biosystems will initially use its "organ-on-a-chip" platform to provide physiologically-relevant "heart-on-a-chip" human tissue models for both toxicology and drug discovery applications.
TINY: 3.24 (+0.06)
Harris & Harris Group Notes Portfolio Company ABS Materials' New Chief Executive Officer
GlobeNewswire - Mon Sep 22, 8:53AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its portfolio company, ABS Materials, Inc., has selected J. Gary McDaniel to lead the company as Chief Executive Officer effective September 3, 2014.
TINY: 3.24 (+0.06), HON: 104.38 (+0.88)
Harris & Harris Group Letter to Shareholders on Website
GlobeNewswire - Tue Aug 19, 8:40AM CDT
Shareholders of Harris & Harris Group, Inc., (Nasdaq:TINY) may be interested to know that we have posted our Quarterly Letter to Shareholders on our website. It may be accessed directly at http://ir.hhvc.com/letters.cfm.
TINY: 3.24 (+0.06)
Harris & Harris Group Reports Financial Statements as of June 30, 2014
GlobeNewswire - Fri Aug 08, 3:36PM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, reported today that, as of June 30, 2014, its net asset value and net asset value per share were $120,878,223 and $3.87, respectively.
TINY: 3.24 (+0.06)
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral"
(formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral.
TINY: 3.24 (+0.06)
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
TINY: 3.24 (+0.06), PFE: 34.64 (-0.23)
Accelerator Corporation Secures $51.1 Million to Support Emerging Biotechnology Research Opportunities in New York City and Seattle
Business Wire - Tue Jul 29, 6:00AM CDT
--Includes New Strategic Investors Eli Lilly and Company, Harris & Harris Group, Inc., Johnson & Johnson Development Corporation, The Partnership Fund for New York City, and Pfizer Venture Investments
JNJ: 99.62 (+1.18), TINY: 3.24 (+0.06), ARE: 94.90 (-1.29)
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014
GlobeNewswire - Wed Jul 23, 2:46PM CDT
The management of Harris & Harris Group, Inc., (Nasdaq:TINY), will hold a conference call to discuss the Company's financial results for its second quarter 2014, to update shareholders and analysts on our business and to answer questions, on Friday, August 15, 2014, at 10:00 a.m. Eastern Time.
TINY: 3.24 (+0.06)
Harris & Harris Group Invests in UberSeq, Inc.
GlobeNewswire - Wed Jul 16, 9:05AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, announced today its investment in UberSeq, Inc. Harris & Harris Group invested $500,000 in UberSeq's Series Seed Financing in June of 2014. UberSeq is a translational genomics company that originated from Stanford University.
TINY: 3.24 (+0.06)
Harris & Harris Group Portfolio Company D-Wave Systems Closes a $28.4 Million Financing
GlobeNewswire - Mon Jul 14, 11:18AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, announced today its participation in portfolio company D-Wave Systems, Inc.'s $28.4 million financing, alongside new and existing investors, including Fidelity Canada Fund, Goldman Sachs, Business Development Bank of Canada, and Draper Fisher Jurvetson. Harris & Harris Group invested approximately $935,000 in this financing, bringing its cumulative investment in D-Wave to $5.8 million.
TINY: 3.24 (+0.06)
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Produced Water Absorbents, Inc.
GlobeNewswire - Wed Jul 09, 9:17AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, released its blog post on Produced Water Absorbents, Inc., and why it is on the cutting edge of the renaissance in oil and gas technologies.
TINY: 3.24 (+0.06)
ORIG3N(TM) Closes $3.1 Million in Funding Lead by Hatteras Venture Partners
PR Newswire - Thu Feb 05, 10:30AM CST
ORIG3N, Inc., a pioneer in regenerative medicine and provider of pluripotent stem cell storage, has raised $3.1 million in funding from an investor syndicate that includes Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital. The funding will be used to expand Life Capsule(TM) which provides everyone the opportunity to contribute to the advancement of medical research of rare genetic inherited diseases and neurodegenerative diseases such as Parkinson's, Alzheimer's, MS and ALS.
TINY: 3.24 (+0.06)
BDCA Venture Switches Investment Strategy, Should Investors Follow?
Chris Katje - at Seeking Alpha - Mon Feb 02, 11:05PM CST
TINY: 3.24 (+0.06), MM: 1.67 (+0.07), TRUE: 19.55 (+0.12), BDCV: 4.95 (+0.07)
Harris & Harris Group Portfolio Company D-Wave Systems Raises an Additional $29 Million (CAD), Closing 2014 Financing at $62 Million (CAD)
GlobeNewswire - Fri Jan 30, 9:40AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by portfolio company, D-Wave Systems, Inc., that it has closed $29 million (CAD) in funding from a large institutional investor, among others. This funding will be used to accelerate development of D-Wave's quantum hardware and software and expand the software application ecosystem. This investment brings total funding in D-Wave to $174 million (CAD), with approximately $62 million (CAD) raised in 2014. Harris & Harris Group's total investment in D-Wave is approximately $5.8 million (USD). D-Wave's announcement also includes highlights of 2014, a year of strong growth and advancement for D-Wave.
TINY: 3.24 (+0.06)
BDCL Next Quarterly Dividend Will Result In A 20.2% Yield
Lance Brofman - at Seeking Alpha - Fri Dec 26, 2:49PM CST
ACAS: 14.68 (+0.14), MAIN: 30.82 (+0.23), TCAP: 22.52 (+0.37), CEFL: 22.43 (+0.06), MTGE: 18.33 (+0.01), CSWC: 46.54 (+1.20), AGNC: 21.95 (+0.21), BDCS: 22.99 (+0.10), MORL: 19.93 (+0.09), TAXI: 9.92 (+0.13), TINY: 3.24 (+0.06), TCPC: 16.39 (+0.17), SPY: 209.78 (+0.86), BDCL: 21.37 (+0.33), ARCC: 16.85 (+0.01), MCGC: 3.84 (-0.01), TSLX: 17.78 (+0.07), ACSF: 12.81 (+0.04), GAIN: 7.69 (+0.05), PSEC: 8.67 (+0.07)
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 3.24 (+0.06), MRK: 58.81 (-0.07)
Harris & Harris Group's (TINY) CEO Douglas Jamison on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:40AM CST
TINY: 3.24 (+0.06)
Harris & Harris reports Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:49AM CST
TINY: 3.24 (+0.06)
Harris & Harris Group Reports Financial Statements as of September 30, 2014
GlobeNewswire - Mon Nov 10, 4:09PM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, reported today that, as of September 30, 2014, its net asset value and net asset value per share were $120,158,974 and $3.85, respectively. The firm has made significant new investments in new emerging areas of science. It has seen growth within its portfolio as its companies continue to execute in their respective industries.
TINY: 3.24 (+0.06)
Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014
GlobeNewswire - Mon Nov 03, 2:53PM CST
The management of Harris & Harris Group, Inc., (Nasdaq:TINY), will hold a conference call to discuss the Company's financial results for its third quarter 2014, to update shareholders and analysts on our business and to answer questions, on Wednesday, November 12, 2014, at 10:00 a.m. Eastern Time.
TINY: 3.24 (+0.06)
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies
GlobeNewswire - Wed Oct 22, 8:52AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, continues its track record of early stage investments in emerging new technologies through a capital commitment and formation of TARA Biosystems (www.tarabiosystems.com). Based on research out of Columbia University, the Radisic Laboratory and MIT, TARA Biosystems aims to capitalize on the need for more effective processes for evaluating the safety and efficacy of new therapies and new drug compounds. TARA Biosystems will initially use its "organ-on-a-chip" platform to provide physiologically-relevant "heart-on-a-chip" human tissue models for both toxicology and drug discovery applications.
TINY: 3.24 (+0.06)
Harris & Harris Group Notes Portfolio Company ABS Materials' New Chief Executive Officer
GlobeNewswire - Mon Sep 22, 8:53AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its portfolio company, ABS Materials, Inc., has selected J. Gary McDaniel to lead the company as Chief Executive Officer effective September 3, 2014.
TINY: 3.24 (+0.06), HON: 104.38 (+0.88)
Harris & Harris Group Letter to Shareholders on Website
GlobeNewswire - Tue Aug 19, 8:40AM CDT
Shareholders of Harris & Harris Group, Inc., (Nasdaq:TINY) may be interested to know that we have posted our Quarterly Letter to Shareholders on our website. It may be accessed directly at http://ir.hhvc.com/letters.cfm.
TINY: 3.24 (+0.06)
Harris & Harris Group Reports Financial Statements as of June 30, 2014
GlobeNewswire - Fri Aug 08, 3:36PM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, reported today that, as of June 30, 2014, its net asset value and net asset value per share were $120,878,223 and $3.87, respectively.
TINY: 3.24 (+0.06)
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral"
(formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral. TINY: 3.24 (+0.06)
Harris & Harris Group Invests in Unique NYC Biotech Accelerator
GlobeNewswire - Tue Jul 29, 7:45AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that it is one of the founding investors in the expansion of Accelerator Corporation, an investment vehicle for emerging biotechnology companies, into New York City. Accelerator is the result of collaboration between a consortium of top-tier venture capital and corporate investors, scientific thought leaders, and executive managers who will identify, finance and manage the development of a select group of early stage biotechnology companies. As part of its participation, Harris & Harris Group Managing Director Misti Ushio, Ph.D., will join the board of Accelerator in New York City.
TINY: 3.24 (+0.06), PFE: 34.64 (-0.23)
Accelerator Corporation Secures $51.1 Million to Support Emerging Biotechnology Research Opportunities in New York City and Seattle
Business Wire - Tue Jul 29, 6:00AM CDT
--Includes New Strategic Investors Eli Lilly and Company, Harris & Harris Group, Inc., Johnson & Johnson Development Corporation, The Partnership Fund for New York City, and Pfizer Venture Investments
JNJ: 99.62 (+1.18), TINY: 3.24 (+0.06), ARE: 94.90 (-1.29)
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014
GlobeNewswire - Wed Jul 23, 2:46PM CDT
The management of Harris & Harris Group, Inc., (Nasdaq:TINY), will hold a conference call to discuss the Company's financial results for its second quarter 2014, to update shareholders and analysts on our business and to answer questions, on Friday, August 15, 2014, at 10:00 a.m. Eastern Time.
TINY: 3.24 (+0.06)
Harris & Harris Group Invests in UberSeq, Inc.
GlobeNewswire - Wed Jul 16, 9:05AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, announced today its investment in UberSeq, Inc. Harris & Harris Group invested $500,000 in UberSeq's Series Seed Financing in June of 2014. UberSeq is a translational genomics company that originated from Stanford University.
TINY: 3.24 (+0.06)
Harris & Harris Group Portfolio Company D-Wave Systems Closes a $28.4 Million Financing
GlobeNewswire - Mon Jul 14, 11:18AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, announced today its participation in portfolio company D-Wave Systems, Inc.'s $28.4 million financing, alongside new and existing investors, including Fidelity Canada Fund, Goldman Sachs, Business Development Bank of Canada, and Draper Fisher Jurvetson. Harris & Harris Group invested approximately $935,000 in this financing, bringing its cumulative investment in D-Wave to $5.8 million.
TINY: 3.24 (+0.06)
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Produced Water Absorbents, Inc.
GlobeNewswire - Wed Jul 09, 9:17AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, released its blog post on Produced Water Absorbents, Inc., and why it is on the cutting edge of the renaissance in oil and gas technologies.
TINY: 3.24 (+0.06)
